iBio (NYSE:IBIO) Upgraded at StockNews.com

StockNews.com upgraded shares of iBio (NYSE:IBIO) to a sell rating in a report issued on Tuesday.

iBio Price Performance

IBIO opened at $4.56 on Tuesday. iBio has a 1 year low of $1.07 and a 1 year high of $6.89. The company’s 50 day simple moving average is $3.92 and its 200 day simple moving average is $2.94. The company has a debt-to-equity ratio of 0.05, a current ratio of 1.76 and a quick ratio of 1.76.

Insider Activity at iBio

In other news, Director David Arkowitz acquired 18,382 shares of the business’s stock in a transaction dated Friday, January 10th. The shares were bought at an average cost of $2.72 per share, for a total transaction of $49,999.04. Following the acquisition, the director now directly owns 18,382 shares in the company, valued at $49,999.04. This trade represents a ∞ increase in their position. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. 0.58% of the stock is owned by insiders.

Institutional Trading of iBio

A hedge fund recently raised its stake in iBio stock. Geode Capital Management LLC lifted its holdings in iBio, Inc. (NYSE:IBIO) by 52.3% in the 4th quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 83,797 shares of the company’s stock after acquiring an additional 28,775 shares during the period. Geode Capital Management LLC owned approximately 0.85% of iBio worth $205,000 as of its most recent SEC filing. 7.90% of the stock is owned by hedge funds and other institutional investors.

iBio Company Profile

iBio, Inc, a biotechnology company, engages in the development of precision antibodies in the United States. It offers IBIO-100, a preclinical anti-fibrotic program for the treatment of systemic scleroderma and idiopathic pulmonary fibrosis; and EngageTx platform, which provides an optimized CD3 T-cell engager antibody panel.